Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
Niloy Chakrabarti

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program.

Vaccine maker Moderna's (NASDAQ: MRNA) stock prices fell by over 16% on 13th January to close at £28.81 ($35.15) after the company trimmed its 2025 revenue guidance to between £1.22 billion ($1.5 billion) and £2.04 billion ($2.5 billion) from its previous estimate between £2.04 billion ($2.5 billion) and £2.86 billion ($3.5 billion).

Wall Street expected a sales outlook of £2.39 billion ($2.92 billion). One year ago, analysts predicted Moderna's 2025 sales to reach £4.1 billion ($5 billion).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.